Cargando…
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dua...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415834/ https://www.ncbi.nlm.nih.gov/pubmed/34485347 http://dx.doi.org/10.3389/fmed.2021.721286 |
_version_ | 1783748045408567296 |
---|---|
author | Speer, Claudius Morath, Christian Töllner, Maximilian Buylaert, Mirabel Göth, Daniel Nusshag, Christian Kälble, Florian Schaier, Matthias Grenz, Julia Kreysing, Martin Reichel, Paula Hidmark, Asa Ponath, Gerald Schnitzler, Paul Zeier, Martin Süsal, Caner Klein, Katrin Benning, Louise |
author_facet | Speer, Claudius Morath, Christian Töllner, Maximilian Buylaert, Mirabel Göth, Daniel Nusshag, Christian Kälble, Florian Schaier, Matthias Grenz, Julia Kreysing, Martin Reichel, Paula Hidmark, Asa Ponath, Gerald Schnitzler, Paul Zeier, Martin Süsal, Caner Klein, Katrin Benning, Louise |
author_sort | Speer, Claudius |
collection | PubMed |
description | Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity. |
format | Online Article Text |
id | pubmed-8415834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84158342021-09-04 Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 Speer, Claudius Morath, Christian Töllner, Maximilian Buylaert, Mirabel Göth, Daniel Nusshag, Christian Kälble, Florian Schaier, Matthias Grenz, Julia Kreysing, Martin Reichel, Paula Hidmark, Asa Ponath, Gerald Schnitzler, Paul Zeier, Martin Süsal, Caner Klein, Katrin Benning, Louise Front Med (Lausanne) Medicine Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity. Frontiers Media S.A. 2021-08-17 /pmc/articles/PMC8415834/ /pubmed/34485347 http://dx.doi.org/10.3389/fmed.2021.721286 Text en Copyright © 2021 Speer, Morath, Töllner, Buylaert, Göth, Nusshag, Kälble, Schaier, Grenz, Kreysing, Reichel, Hidmark, Ponath, Schnitzler, Zeier, Süsal, Klein and Benning. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Speer, Claudius Morath, Christian Töllner, Maximilian Buylaert, Mirabel Göth, Daniel Nusshag, Christian Kälble, Florian Schaier, Matthias Grenz, Julia Kreysing, Martin Reichel, Paula Hidmark, Asa Ponath, Gerald Schnitzler, Paul Zeier, Martin Süsal, Caner Klein, Katrin Benning, Louise Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title | Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_full | Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_fullStr | Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_full_unstemmed | Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_short | Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_sort | humoral responses to single-dose bnt162b2 mrna vaccination in dialysis patients previously infected with sars-cov-2 |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415834/ https://www.ncbi.nlm.nih.gov/pubmed/34485347 http://dx.doi.org/10.3389/fmed.2021.721286 |
work_keys_str_mv | AT speerclaudius humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT morathchristian humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT tollnermaximilian humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT buylaertmirabel humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT gothdaniel humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT nusshagchristian humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT kalbleflorian humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT schaiermatthias humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT grenzjulia humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT kreysingmartin humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT reichelpaula humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT hidmarkasa humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT ponathgerald humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT schnitzlerpaul humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT zeiermartin humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT susalcaner humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT kleinkatrin humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT benninglouise humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 |